Our research focus is to leverage genomic and stem cell technologies to study and solve the causes of neural injury and disease. As part of the W.M. Keck Center for Collaborative Neuroscience and the Rutgers Stem Cell Research Center, we share several collaborative projects with our colleagues.
- Risk gene variants in addiction disorders Beginning with a collaboration with Dr. Jay Tischfield, we built collections of human induced pluripotent stem cells (iPSC) with selected subjects from the large-scale screening for genetic variants associated with nicotine and alcohol abuse. Our current focus is on alcoholism risk variants from the COGA project. These projects are all in collaboration with Dr. Zhiping Pang of the Rutgers Child Health Institute. Our goal is to identify mechanisms in human neurons that predict optimal therapies based on specific genetic variants. Earlier work identified neuronal function differences due to a variant of the CHRNA5 gene (Oni et al., 2016), associated with nicotine addiction. Another study focused on variants of the OPRM1 mu-opioid receptor genes (Halikere et al., 2019). Current projects, part of the large COGA study, focus on gene variants associated with alcoholism.
- Genetic and toxin risk in Alzheimer’s Together with Dr. Jason Richardson, we have prepared iPSC from Alzheimer’s disease (AD) subjects carrying variants of the APOE gene, which is the greatest genetic risk factor for AD. Dr. Richardson has found that exposure to DDT or its metabolite DDE, particularly in subjects carrying the APOE ε4/ε4 variant, compounds the risk for AD. This is a unique example of a gene x environment interaction for a major neurodegenerative disorder. Our role in the project is to using human neurons to model DDT action on APOE gene variants to stimulate AD-related mechanisms.
- Ataxia-telangiectasia Our recent article in the Journal of Cell Biology was introduced by a Spotlight summary. This work identifies the novel ATP/ROS sensing capacity of ATM, leading to regulation of mitochondrial function via activation of Nrf1. Based on previous collaborative projects with the laboratory of Dr. Karl Herrup (Li et al., 2012, Nature Medicine; Li et al., 2013, Nature Neuroscience; Jiang et al., 2015, Brain), we have prepared iPSC from several Ataxia-telangiectasia (A-T) subjects. Source cells for iPSC reprogramming were collected at the Ataxia-telangiectasia Clinical Center at The Johns Hopkins Hospital, under the direction of Dr. Howard Lederman. Among the A-T iPSC produced, we identified a spontaneous ATM gene reversion, providing us with an isogenic pair of iPSC lines (ATM– vs. ATM+; Lin et al., 2015 Stem Cell Reports. Our goal is to model the broad genetic diversity present in A-T patients but lacking in traditional models such as mouse knockouts.
- Modeling HIV-associated neurocognitive disorder (HAND) in iPSC-derived cerebral organoids. Working with Drs. Pang, Jiang, and Rabson, we have adapted cerebral organoid models to include iPSC-derived human microglia, so that these cultures may be infected with HIV virus. This was supported as a pilot project by the Rutgers Brain Health Institute.
We collaborated with RUCDR Infinite Biologics® to form the NIMH Stem Cell Center, a service to bank cells from subjects with mental disorders for use in creating induced pluripotent stem cells (iPSC). The Center will also create iPSC as directed by the scientific advisory board. We participate in many collaborative studies to use specific genetic background sample to prepare iPSC in the study of addiction, schizophrenia, Alzheimer’s disease, autism and more. Find our iPSC protocol book here.